Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
CTNNA1 antisense RNA 1 (CTNNA1-AS1) is a long noncoding natural antisense transcript complementary to the CTNNA1 gene. Antisense RNAs like CTNNA1-AS1 are known to regulate the expression of their sense gene at multiple levels, including transcriptional interference, chromatin remodeling, mRNA stability, and translational control. Although no specific studies are published on the molecular mechanisms or disease associations of CTNNA1-AS1, similar NATs have been implicated in cancer and other disease processes by regulating their sense gene. CTNNA1 itself encodes alpha-catenin, which is critical for cell adhesion and acts as a tumor suppressor, so CTNNA1-AS1 may influence tumorigenesis through control of CTNNA1 expression.
Drugs (ASOs) targeting antisense lncRNAs generally act by promoting RNA degradation, modulating splicing, blocking translation, or interfering with regulatory interactions. For CTNNA1-AS1, ASO or RNAi-based approaches could theoretically suppress its expression, which might affect CTNNA1 levels, but no specific mechanism is published.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on CTNNA1 antisense RNA 1 (CTNNA1-AS1).